Ryaltris

Glenmark Pharmaceuticals is a global, research-led pharmaceutical company headquartered in Mumbai, India, with a significant presence in generics, specialty, and over-the-counter markets. The company is widely recognized for developing Ryaltris, an innovative fixed-dose combination nasal spray for the treatment of seasonal allergic rhinitis, which has been launched in numerous global markets including the United States and Europe. Glenmark focuses on key therapeutic areas such as respiratory, dermatology, and oncology, supported by a network of manufacturing facilities and R&D centers worldwide. Through its subsidiary Ichnos Sciences, the company also pursues the development of novel biological entities in oncology and immunology. Glenmark maintains strategic partnerships with major firms like Hikma and Menarini to expand the commercial reach of its specialty portfolio.